Table 3: Therapeutic applications of bone marrow-derived MSCs in liver cirrhosis patients.

Cell type Dose Route Sample size (n) Outcome Reference
BM-MSC Single median dose/unspecified Intrahepatic and intrasplenic 40 Increased serum albumin; Decreased CPS, MELD score, bilirubin and ascites [40]
BM-MSC Single median dose/30-40 × 106 Peripheral vein 4 Improved liver function and Decreased MELD score [48]
BM-MSC Single median dose/31.73 × 106 Peripheral or the portal vein 8 Increased serum albumin; Decreased MELD score, serum creatinine, prothrombin, and bilirubin [10]
BM-MSC Single median dose/unspecified Hepaic artery 572 Increased serum albumin; Decreased MELD score and serum bilirubin [54]
BM-MSC Single median dose/1 × 106 per kg body weight Intravenous 25 Improved serum albumin; Decreased prothrombin, bilirubin and MELD score [55]
BM-MSC Single median dose/10 × 106 Intrasplenic 20 Increased serum albumin; Decreased serum bilirubin, AST, ALT, prothrombin and INR [56]
BM-MSC Single median dose/1.9 × 108 Peripheral vein 27 No significant improvement [9]